Stockreport

Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B [Globe and Mail, The (Toronto, Canada)]

AIM ImmunoTech Inc.  (AIM) 
PDF that once resisted checkpoint inhibitors are finally responding to novel combination strategies [1] , with the FDA fast-tracking multiple targeted therapies designed to [Read more]